Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of body weight on trough concentrations of DOACs
2017-003569-91Phase 4Active
- Sponsor
- HagaZiekenhuis
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of apixaban, dabigatran, edoxaban and rivaroxaban in venous thromboembolism (VTE), nonvalvular atrial fibrillation (NVAF) and anticoagulation therapy (4 arms), sponsored by HagaZiekenhuis. Primary endpoint: DOAC trough concentration. Started Sep 2017; status: active.
02
Drugs
apixabandabigatranedoxabanrivaroxaban
03
Conditions
venous thromboembolism (VTE)nonvalvular atrial fibrillation (NVAF)anticoagulation therapy
Beyond the preview
Go deeper on 2017-003569-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003569-91.